PMID- 24548718
OWN - NLM
STAT- MEDLINE
DCOM- 20150113
LR  - 20140326
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 17
IP  - 3
DP  - 2014 Mar
TI  - Recent advances in Takayasu arteritis.
PG  - 238-47
LID - 10.1111/1756-185X.12309 [doi]
AB  - Takayasu arteritis (TAK) is a relatively rare systemic vasculitis mainly 
      affecting the aorta and its large branches. While patients with TAK are more 
      frequently observed in Asian countries, we can find patients with TAK all over 
      the world. This limited number of patients has made it difficult to collect large 
      numbers of patients and perform detailed studies. However, recent progresses have 
      led to the identification of susceptibility genes and novel susceptibility human 
      leukocyte antigen (HLA) alleles as well as accumulation of clues for the 
      pathophysiology of TAK. IL12B was shown to be a susceptibility gene beyond 
      ethnicity. MLX and FCGR2A/3A were shown to be associated with TAK in Japanese and 
      Turkish/American populations, respectively. HLA-B*52:01 and *67:01 are 
      susceptibility alleles to TAK, and the 171st and 67th amino acid residues of 
      HLA-B protein are suggested important for TAK susceptibility. HLA-DQB1/DRB1 is 
      recently reported as an independent susceptibility locus. Although there are no 
      standardized serum markers or composite measures for disease activity of TAK, 
      Japanese and Italian groups showed pentraxin 3 as a novel biomarker for detecting 
      and monitoring patients with TAK. Recently, an Indian group proposed a novel 
      scoring system called ITAS to evaluate disease activity of TAK. Standardization 
      of assessing disease activity would lead to clinical studies with high quality. 
      Several groups reported results of treatment for refractory TAK with biological 
      agents targeting tumor necrosis factor or interleukin-6R. The recent accumulation 
      of research data should improve understanding of the basic pathophysiology of TAK 
      and lead to better management of patients with TAK.
CI  - (c) 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing 
      Asia Pty Ltd.
FAU - Terao, Chikashi
AU  - Terao C
AD  - Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan.
FAU - Yoshifuji, Hajime
AU  - Yoshifuji H
FAU - Mimori, Tsuneyo
AU  - Mimori T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140218
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antirheumatic Agents)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Receptors, Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Animals
MH  - Antirheumatic Agents/*therapeutic use
MH  - Biomedical Research/*trends
MH  - Disease Models, Animal
MH  - Genetic Predisposition to Disease/*genetics
MH  - HLA-DQ beta-Chains/genetics
MH  - HLA-DRB1 Chains/genetics
MH  - Humans
MH  - India
MH  - Interleukin-12/genetics
MH  - Italy
MH  - Japan
MH  - Receptors, Interleukin-6/antagonists & inhibitors
MH  - Rheumatology/*trends
MH  - Takayasu Arteritis/*drug therapy/*genetics/physiopathology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
MH  - Turkey
OTO - NOTNLM
OT  - clinical aspects
OT  - disease aetiology and pathogenesis - human
OT  - drug treatment
OT  - epidemiology
OT  - genetics
EDAT- 2014/02/20 06:00
MHDA- 2015/01/15 06:00
CRDT- 2014/02/20 06:00
PHST- 2014/02/20 06:00 [entrez]
PHST- 2014/02/20 06:00 [pubmed]
PHST- 2015/01/15 06:00 [medline]
AID - 10.1111/1756-185X.12309 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2014 Mar;17(3):238-47. doi: 10.1111/1756-185X.12309. Epub 2014 
      Feb 18.